Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Precision medicine is medicine optimized to the genotypic and phenotypic characteristics of
an individual and, when present, his or her disease. It has a host of targets, including genes …

Increased glycolysis is considered as a hallmark of cancer. Yet, cancer cell metabolic
reprograming during therapeutic resistance development is under-studied. Here, through …

Despite an increasing arsenal of anticancer therapies, many patients continue to have poor
outcomes due to the therapeutic failures and tumor relapses. Indeed, the clinical efficacy of …

Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and
conventional treatments have little impact on survival. Therapeutically, this tumor is poorly …

Metabolic reprogramming is one of the hallmarks of tumors. Alterations of cellular
metabolism not only contribute to tumor development, but also mediate the resistance of …

Background The acquisition of resistance to chemotherapy is a major hurdle in the
successful application of cancer therapy. Several anticancer approaches, including …

Cancer is a daunting global problem confronting the world's population. The most frequent
therapeutic approaches include surgery, chemotherapy, radiotherapy, and more recently …

Ovarian cancer is the most lethal malignancy among the gynecological cancers, with a 5‐
year survival rate, mainly due to being diagnosed at advanced stages, recurrence and …

Trastuzumab resistance has been becoming a major obstacle for treatment of HER-2-
positive breast cancer patients. Increasing evidence suggests that mesenchymal stem cells …